MiMedx Group (NASDAQ:MDXG) Announces Earnings Results

MiMedx Group (NASDAQ:MDXG) issued its earnings results on Wednesday. The company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07, Zacks reports. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%.

MiMedx Group Trading Down 0.1 %

Shares of MiMedx Group stock traded down $0.01 during trading on Friday, hitting $8.14. The stock had a trading volume of 272,862 shares, compared to its average volume of 567,597. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $1.20 billion, a PE ratio of 14.79 and a beta of 1.94. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $10.14. The stock has a 50 day simple moving average of $8.74 and a 200 day simple moving average of $7.68.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on MDXG shares. StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research note on Thursday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $12.40.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.